Loading...
•
Jun 30, 2023
Regeneron Q2 2023 Earnings Report
Regeneron's financial performance was strong in Q2 2023, driven by diversified revenue streams and pipeline advancements.
Key Takeaways
Regeneron reported an 11% increase in revenue to $3.16 billion for the second quarter of 2023. GAAP diluted EPS was $8.50, and non-GAAP diluted EPS was $10.24. The company progressed its pipeline, including aflibercept 8 mg, and saw a 33% increase in Dupixent global net sales.
Total revenues increased by 11% to $3.16 billion compared to Q2 2022.
Dupixent global net sales (recorded by Sanofi) increased by 33% to $2.79 billion compared to Q2 2022.
EYLEA U.S. net sales were $1.50 billion.
GAAP diluted EPS was $8.50, and non-GAAP diluted EPS was $10.24.
Regeneron
Regeneron
Regeneron Revenue by Segment
Revenue by Segment
Net Product Sales Revenue
CapyFin.com Forward Guidance
Regeneron updated its full year 2023 financial guidance.
Positive Outlook
- GAAP R&D guidance updated to $4.315–$4.455 billion.
- Non-GAAP R&D guidance updated to $3.825–$3.925 billion.
- GAAP SG&A guidance updated to $2.540–$2.680 billion.
- Non-GAAP SG&A guidance updated to $2.180–$2.280 billion.
- GAAP effective tax rate updated to 8%-9%.
Challenges Ahead
- No specific negative aspects were provided, the guidance update mainly involved adjustments to projected figures without highlighting explicit concerns or risks.